Due Diligence (7)

Challenge Alacrita’s pharma consultants were engaged to conduct a due diligence and valuation of a Phase II dermatology asset.

Challenge A start-up company was planning to license an immunomodulatory product from a European pharmaceutical company. The therapy had been unsuccessfully tried in allergic disorders, but the...

Challenge A university research team had worked for a number of years on the development of a novel interventional cardiology device. Recent progress had been made with preclinical testing on pigs,...

Challenge A company considering an investment in a new early-stage biosensor technology for the measurement of blood pressure needed due diligence support. The product had a number of potential...

Challenge A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment.

Challenge Our client asked us to conduct a risk assessment and due diligence of a small molecule oncology compound that had been identified from a phenotypic screen. The molecule was in a Phase I/II...

Challenge We were commissioned to conduct a comprehensive technical risk assessment and due diligence of a novel preclinical, small molecule, kinase inhibitor.

Challenge A major European venture capital investor needed help to review the business plan and competitive positioning of a novel point-of-care diagnostics company. The company was developing a...

Challenge A clinical stage, type 1 diabetes immunotherapy project needed convincing partnering materials and advice on data room structure and due diligence preparations.

Challenge A European pharma company needed to conduct an expert reality check on a pain in-licensing opportunity.

Challenge An established medical device company looking to make a strategic investment needed commercial, regulatory, IP and technical due diligence on an investment opportunity in the diabetes...

Challenge A major UK bioscience investor needed due diligence on a cell biology reagents investment opportunity.